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Abstract
Background: The aims of the present study were to determine the relationship between bone destruction and
bone formation in the delayed-type hypersensitivity arthritis (DTHA) model and to evaluate the effect of receptor
activator of nuclear factor κB ligand (RANKL) blockade on severity of arthritis, bone destruction, and bone formation.
Methods: DTHA was induced in C57BL/6 mice. Inflammation, erosive joint damage, and new bone formation
were semiquantitatively scored by histology. Osteoclast activity was assessed in vivo, and messenger RNA (mRNA)
expression of mediators of bone destruction and bone formation were analyzed by mRNA deep sequencing.
Serum concentrations of tartrate-resistant acid phosphatase 5b, carboxy-terminal telopeptide I (CTX-I), matrix
metalloproteinase 3 (MMP3), and serum amyloid P component (SAP) were determined by enzyme-linked
immunosorbent assay. Anti-RANKL monoclonal antibody treatment was initiated at the time of immunization.
Results: Bone destruction (MMP3 serum levels, cathepsin B activity, and RANKL mRNA) peaked at day 3 after
arthritis induction, followed by a peak in cartilage destruction and bone erosion on day 5 after arthritis induction.
Periarticular bone formation was observed from day 10. Induction of new bone formation indicated by enhanced
Runx2, collagen X, osteocalcin, MMP2, MMP9, and MMP13 mRNA expression was observed only between days 8
and 11. Anti-RANKL treatment resulted in a modest reduction in paw and ankle swelling and a reduction of serum
levels of SAP, MMP3, and CTX-I. Destruction of the subchondral bone was significantly reduced, while no effect on
bone formation was seen.
Conclusions: Anti-RANKL treatment prevents joint destruction but does not prevent new bone formation in the
DTHA model. Thus, although occurring sequentially during the course of DTHA, bone destruction and bone
formation are apparently not linked in this model.
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Background
Chronic joint inflammation in rheumatoid arthritis (RA)
and spondyloarthritis (SpA) leads to disease-specific re-
actions in the adjacent joint structures. In RA, which
mainly affects peripheral joints, chronic inflammation is
characterized by synovial hyperplasia, pannus formation,
cartilage destruction, and bone erosion, leading to de-
struction of joint architecture and function [1, 2]. In
axial SpA, chronic inflammation predominantly affects
the sacroiliac joints and vertebral bodies [3]. This is ac-
companied by local bone erosion and more prominent
new bone formation, leading to joint ankylosis and syn-
desmophyte development [4]. In addition, new bone for-
mation may develop at sites of peripheral enthesial
inflammation in SpA [5], which is a particularly promin-
ent finding in psoriatic arthritis [6].
Matrix-degrading enzymes, osteoclasts, and invasion
of chronically activated synoviocytes are implicated in
bone destruction in RA [7–9], but little is known about
the mechanisms involved in inflammation-driven new
bone formation, occurring mostly in SpA rather than in
RA. Histological analysis of facet joints from patients
with ankylosing spondylitis (AS), the progressed form of
axial SpA, showed erosive damage of the subchondral
bone from the bone marrow side. This damage is driven
by osteoclasts located at the leading edge of a subchon-
dral fibroblast-rich granulation tissue [10], which invades
the subchondral bone. New bone formation has been
linked to this subchondral pannus [11, 12], suggesting
that bone destruction and new bone formation could be
linked. In contrast, in mouse models of SpA, specifically
in the DBA/1 model, where grouped caging of male
DBA/1 mice leads to development of ankylosing enthesi-
tis [13], destruction and bone formation do not seem to
be linked, because inhibition of osteoclast function does
not prevent new bone formation [14].
The delayed-type hypersensitivity arthritis (DTHA)
model is a new inflammatory arthritis model in C57BL/6
mice. It combines collagen type II antibody (anti-CII)
administration with local DTH induction in the footpad,
which leads to severe arthritis and periarticular inflam-
mation, including enthesial sites [15]. Arthritis develop-
ment is dependent on CD4+ cells and proinflammatory
cytokines and is characterized by bone and cartilage
destruction, pannus formation, and osteophyte develop-
ment at sites of periarticular inflammation. Prophylactic
tumor necrosis factor α (TNFα) blockade not only re-
duces inflammation and bone erosion but also prevents
new bone formation [15], indicating that both bone
destruction and bone formation are triggered by inflam-
mation in this model.
In this study, we determined the relationship between
bone destruction and new bone formation in the DTHA
model. We investigated the spatiotemporal occurrence
of bone destruction and new bone formation by histo-
logical analysis, by performing an expression analysis of
genes involved in tissue destruction and bone formation,
and by analysis of the effect of preventive receptor acti-
vator of nuclear factor κB ligand (RANKL) blockade.
Cartilage destruction and bone erosion peaked early
after arthritis induction, while periarticular bone forma-
tion occurred later in the disease course. Bone erosion
was accompanied by osteoclastogenesis and high levels
of local bone resorptive activity, followed by induction of
genes related to endochondral and direct bone forma-
tion. Anti-RANKL treatment had a modest effect on in-
flammation and prevented bone resorption but did not
affect bone formation, indicating that bone formation
and destruction are not linked in the DTHA model.
Methods
Animals
Female 8–10-week-old C57BL/6 J mice were purchased
from Taconic (Ry, Denmark). Animals were housed in a
temperature- and humidity-controlled facility with a 12-
h light/dark cycle and with free access to water and
standard rodent chow (Altromin®; Altromin Spezialfut-
ter, Lage, Germany). All animal experiments were con-
ducted according to Danish legislation and were
approved by the Danish Animal Inspectorate and the
Novo Nordisk ethical review board.
Induction and assessment of DTHA
DTHA was induced as described previously [15]. In
brief, mice were immunized intradermally with methyl-
ated bovine serum albumin (mBSA; Sigma-Aldrich, St.
Louis, MO, USA) emulsified in Difco complete Freund’s
adjuvant (CFA; BD Diagnostics, Sparks, MD, USA) at
the base of the tail. Four days later, mice were given
1000 μg (approximately 50 mg/kg) of anti-mouse anti-
CII cocktail (Chondrex, Redmond, WA, USA) intraven-
ously (i.v.) in 200 μl of phosphate-buffered saline (PBS).
Seven days after immunization, the mice were chal-
lenged with 200 μg of mBSA subcutaneously in 20 μl of
PBS in the right footpad and as a control with 20 μl of
PBS in the left footpad. Paw and ankle swelling was
measured using a dial thickness gauge (Mitutoyo, Kana-
gawa, Japan) and change in swelling on day x was calcu-
lated by subtracting swelling measured on day 0 from
swelling measured on day x.
Blockade of RANKL
Five hundred micrograms of anti-RANKL monoclonal
antibody (mAb; clone IK22/5) or rat immunoglobulin
G2a (IgG2a) isotype control (Bio X Cell, West Lebanon,
NH, USA) were injected intraperitoneally in 200 μl of
PBS three times weekly from the time of immunization.
The experimenter was blinded to the treatment groups.
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Histopathology
For histopathological evaluation, paws were fixed in 4 %
paraformaldehyde, decalcified for 7 days, dehydrated,
and embedded in paraffin. Sections of 3–5 μm were cut
and deparaffinized for histopathological evaluation.
For overview, paws were stained with hematoxylin
and eosin (H&E). For detection of cartilage destruc-
tion, Safranin O staining was performed. Collagen type
X (COLX)-positive hypertrophic chondrocytes and
osteocalcin-positive osteoblasts were detected by immu-
nohistochemical staining. Osteoclasts were histochemically
stained for tartrate-resistant acid phosphatase (TRAP;
Kamiya Biomedical, Seattle, WA, USA). For osteocalcin
staining, heat-induced epitope retrieval at 100 °C for 30 mi-
nutes in citrate buffer (pH 6.0) and subsequent enzymatic
retrieval with proteinase K (Dako, Glostrup, Denmark) at
37 °C for 7 minutes was used. For COLX detection, a
double enzymatic retrieval with protease (Sigma-Aldrich)
in Tris-buffered saline (TBS; 2 mg/ml) at 37 °C for 15 mi-
nutes and hyaluronidase (Sigma-Aldrich) in TBS (2 mg/ml)
at 37 °C for 150 minutes was used. After blocking of non-
specific binding by goat serum (10 %; Dianova, Hamburg,
Germany) for 15 minutes, sections were incubated with
anti-osteocalcin (polyclonal rabbit, dilution 1:500; Enzo Life
Sciences AG, Lausen, Switzerland) and anti-COLX (clone
X53, dilution 1:25; Quartett Immunodiagnostics, Berlin,
Germany) overnight at 4 °C. After blocking of en-
dogenous biotin with an Invitrogen avidin–biotin-
blocking kit (Thermo Fisher Scientific, Paisley, UK)
the slides were incubated for 1 h with species-specific
biotinylated immunoglobulin (Dianova) and for 1 h
with alkaline phosphatase (ALP)-streptavidin (Vector
Laboratories, Burlingame, CA, USA). ALP was visual-
ized using Chromogen Red (Dako REAL Detection
System Kit; Dako) before counterstaining with Mayer’s
hematoxylin. As negative controls, experiments were
performed (1) with isotype controls for IgG and (2)
by omitting the primary antibodies.
Histopathological scoring of DTHA paws
Pathological changes in the metatarsal and tarsal joints
of the paws were semiquantitatively assessed. The extent
of inflammation and of periarticular and subchondral
pannus tissue was assessed on H&E-stained sections, the
extent of cartilage and bone damage was assessed on
Safranin O/Fast Green–stained sections, and the extent
and type of new bone formation were assessed on
COLX- and osteocalcin-stained sections, each on a scale
of 0–3 (no, minimal, moderate, or severe). Results are
given as mean ± standard error of the mean (SEM).
Microscope, camera, and software
Scoring was performed using an Olympus BX60 micro-
scope (Olympus, Hamburg, Germany). Pictures were
taken with a digital camera (Color View II Soft Imaging
System; Olympus Soft Imaging Solutions GmbH, Mün-
ster, Germany) and analyzed using analytical software
(Soft Imaging Software Cell D; Olympus Soft Imaging
Solutions GmbH).
Enzyme-linked immunosorbent assays
Serum levels of the following markers were determined
employing commercially available enzyme-linked im-
munosorbent assays: RANKL, matrix metalloproteinase
3 (MMP3) (both from R&D Systems, Minneapolis, MN,
USA), TRAP5b and carboxy terminal telopeptide I (CTX-
I) [both from Immunodiagnostic Systems (IDS), Tyne &
Weir, UK] and serum amyloid P component (SAP;
GenWay Biotech, San Diego, CA, USA). Results are dis-
played as mean ± SEM.
In vivo imaging of bone erosion activity using
fluorescence molecular tomography
Mice were injected i.v. with 4 nmol of the probe Cat B
750 FAST dissolved in PBS (PerkinElmer, Waltham,
MA, USA). Cat B 750 FAST is a cathepsin B activatable
fluorescence agent. It is optically silent upon injection
but cleaves upon contact with cathepsin B, thereby
emitting a fluorescent signal. Mice were scanned ap-
proximately 20 h after probe injection. Mice were anes-
thetized with isoflurane and gently placed in a dorsal
position in the fluorescence molecular tomography
(FMT) cassette. Their paws were placed on FMT scanner
blocks and kept in place with surgical tape. The cassette
was inserted into the FMT scanner in a heated environ-
ment and with the mice under continuous inhalation
anesthesia. The mice were scanned at 750 nm with the
FMT 2000 scanner (PerkinElmer). The data are pre-
sented as the relative picomolar fluorescence in the right
hind paw with the control value obtained from the left
(control) hind paw subtracted.
mRNA deep sequencing
Paws were homogenized in Qiagen Buffer RLT (Qiagen,
Germantown, MD, USA) with 1 % β-mercaptoethanol
(Sigma-Aldrich) and stored at −80 °C before total RNA
isolation using the Ambion MagMAX preparation
protocol (Thermo Fisher Scientific). After RNA quality
control using an Agilent Bioanalyzer (Agilent Technolo-
gies, Santa Clara, CA, USA) and assessment of RNA
quantity using a NanoDrop instrument (NanoDrop
Products, Wilmington, DE, USA), RNAseq libraries were
prepared from 120 ng of total RNA with an Illumina
TruSeq Sample Prep Kit (Illumina, San Diego, CA,
USA). Barcode adapters were added to samples in such a
way as to allow pooling of samples in flow cell lanes in a
randomized pattern relative to sample annotation and
source. Samples were sequenced using an Illumina
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HiSeq 2000 system (Illumina) at a multiplexing level suf-
ficient to generation 10 million to 25 million reads per
sample. Following generation of sequences, reads were
aligned to mouse genome NCBI Build 37 (mm9) using
TopHat (http://tophat.cbcb.umd.edu/). Quality control
of the sequencing data was accomplished by using the
ShortRead package in R (http://www.r-project.org/).
Aligned reads were mapped to Ensembl transcript
models and converted to reads per kilobase per million
values using Cufflinks (http://cufflinks.cbcb.umd.edu/).
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 5 for Windows Version 5.01 software (GraphPad
Software, La Jolla, CA, USA). Nonparametric data or
nonnormal parametric data of two groups were analyzed
by using the Mann–Whitney U test, and parametric data
were analyzed by using a two-sided unpaired t test or
one-way analysis of variance. For multiple group com-
parisons, the Kruskal–Wallis test and Dunn’s multiple
comparisons test as a posttest were used. A p value
less than 0.05 was considered significant, and levels
of significance were assigned as *p ≤ 0.05, **p ≤ 0.01,
and ***p ≤ 0.001.
Results
Pathology in DTHA is characterized by early development
of periarticular and subchondral pannus tissue
To examine tissue pathology in the DTHA model, we
induced DTHA as described previously [15] and per-
formed an extensive histopathological analysis with the
purpose of assessing inflammation, pannus formation,
tissue destruction, and new bone formation. In brief,
C57BL/6 J mice were immunized with mBSA in CFA,
followed 4 days later by intravenous administration of a
cocktail of anti-CII mAbs. One week after immunization,
the mice were challenged with mBSA in the right hind
paw and with PBS in the left hind paw as a control.
A maximum of swelling of the mBSA-challenged right
hind paw was observed on days 3–5 after arthritis induc-
tion (Fig. 1a). Histological assessment revealed massive
synovial and extraarticular inflammation within the
mBSA-challenged paw (Fig. 1b and c). Scoring of inflam-
mation (the magnitude of the cellular infiltrate, score
range 0–3) showed peak inflammation on days 5 and 10
and a decline on day 20 (Fig. 1c). Development of an in-
flammatory periarticular pannus tissue (i.e., a fibroblast-
rich tissue containing mononuclear immune cells at syn-
ovial and periarticular sites, including enthesial attach-
ments at apophyses) was most prominent on day 5 and
day 10 and also declined by day 20 after arthritis induc-
tion (Fig. 1c). Furthermore, we noticed that the normal
bone marrow had been replaced by a fibroblast-rich
granulation tissue infiltrated with mononuclear cells
(similar to pannus tissue at periarticular sites) in sub-
chondral bone marrow regions adjacent to inflamed
joints (Fig. 1b and c). This subchondral granulation tis-
sue was detectable already on day 5 and did not change
in magnitude throughout the study. The left paws
showed no inflammation or periarticular or subchondral
pannus tissue.
Sequential development of joint destruction and new
bone formation
Destruction of the joint structures was assessed by look-
ing at tissue sections stained with Safranin O/Fast
Green, which stains cartilage red and bone blue. Most of
the cartilage damage was seen as cartilage irregularity
and loss of cartilage integrity (Fig. 2a). Bone resorption
facilitated by the periarticular pannus and the subchon-
dral granulation tissue occurred early during arthritis, as
shown in the scoring of cartilage damage and bone re-
sorption (Fig. 2b). This suggests that inflammation dir-
ectly induces a strong osteoclastic and proteolytic
response, which drives tissue destruction.
New bone formation was detectable from day 10
(Fig. 2a and b) and was located at diaphyseal sites and
periarticularly close to apophyseal tendon insertions.
New bone formation was seen as endochondral bone
formation, as shown by the presence of COLX-
expressing hypertrophic chondrocytes, and as direct
bone formation facilitated by osteocalcin-positive osteo-
blasts generating new woven bone (Fig. 2a). Newly
formed COLX-dependent bone was found primarily at
apophyseal sites, while at diaphyseal sites newly formed
woven bone with osteocalcin-positive osteoblasts was
found. In the majority of joints, endochondral and direct
bone formation occurred simultaneously (Fig. 2c).
In this model, new bone formation is preceded by
osteoclastic and proteolytic joint destruction, and this
sequence of events could suggest that bone damage and
new bone formation are linked in DTHA.
Osteoclasts located at apophyseal and subchondral sites
promote bone destruction by the periarticular and
subchondral pannus
Osteoclasts are involved in inflammation-driven bone
destruction [16]. Activated osteoclasts, identified by
TRAP expression, were detectable on day 5 and most
prominently on day 10 after arthritis induction. Osteo-
clasts were found attached to apophyseal and diaphyseal
bone adjacent to the inflamed joints at the edges of the
periarticular pannus tissue and at the edges of the sub-
chondral granulation tissue (Fig. 3). At apophyseal sites,
osteoclasts were also located close to vascular channels
that have been described before penetrating the bone
and connecting the periarticular and/or synovial pannus
with the subchondral bone marrow [17]. On day 10,
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activated osteoclasts were also located close to areas of
direct bone formation at diaphyseal sites.
Tissue response in DTHA involves enhanced proteolytic
and osteoclastic activity and increased transcription of
osteoclast- and osteoblast-specific genes
To identify mediators involved in tissue and bone de-
struction, we assessed inflammatory tissue destruction
by measurement of the activity of cathepsin B, a protease
expressed in fibroblasts and other cells. For this purpose,
we used in vivo FMT and also determined serum levels
of MMP3. The peak of both local cathepsin B activity
and systemic MMP3 levels was synchronized with the
peak of paw swelling (Fig. 4a and b). RANKL messenger
RNA (mRNA) expression in the arthritic paw followed a
similar time course. In contrast, mRNA expression of
TRAP and cathepsin K increased from day 3 and peaked
on day 8 after arthritis induction, reflecting increased os-
teoclastogenesis (Fig. 4c).
Induction of osteoblast-specific genes such as ALP,
osteocalcin, and β-catenin was observed only from day 8
to day 11 when transforming growth factor (TGF)-β1
mRNA expression was also increased. These events were
preceded by the induction of Runx2 mRNA. Expression
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Fig. 1 Inflammation in delayed-type hypersensitivity arthritis (DTHA) is accompanied by periarticular pannus and subchondral granulation tissue
formation. DTHA was induced by intradermal immunization with methylated bovine serum albumin (mBSA) in complete Freund’s adjuvant at
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of MMP2, MMP9, and MMP13 genes, which are related
to the endochondral ossification pathway and bone re-
modeling [18–20], was also increased in the arthritic
paw up to day 8 after arthritis induction. The expression
of bone morphogenetic protein 2 (BMP2) and BMP7,
which may act as osteoblast growth factors [21], was not
increased in DTHA compared with paws of untreated
naive mice, but it seemed to decrease upon arthritis
induction (Fig. 4c). Interestingly, expression of the
Wingless (Wnt) signaling pathway inhibitor Dickkopf
(DKK)-1 was increased only on day 8, and no dysregula-
tion was seen at early time points during acute arthritis.
Preventive anti-RANKL treatment completely prevents
bone erosion but has only a slight anti-inflammatory ef-
fect on DTHA
To investigate the relationship between bone destruction
and new bone formation, as well as to clarify the impact
of osteoclasts and specifically RANKL-dependent osteo-
clast activation and differentiation on arthritis severity,
bone destruction, and new bone formation, we treated
mice with an anti-RANKL mAb or an isotype control
antibody from the time of mBSA immunization. Anti-
RANKL treatment resulted in a slight reduction of paw
and ankle swelling, primarily at later time points (Fig. 5a).
Moreover, it also lowered levels of systemic inflamma-
tion markers compared with isotype-treated mice. This
effect was more obvious at early time points, specifically
at day 0 (i.e., before challenge) and at day 7 after DTHA
induction (Fig. 5b). The fact that anti-RANKL treatment
resulted in lower SAP and MMP3 serum levels before
challenge suggests that anti-RANKL treatment also af-
fects the response to immunization.
Treatment with anti-RANKL mAb drastically reduced
TRAP5b serum levels on day 11 after arthritis induction
as well as serum levels of CTX-I (Fig. 5c). Moreover, in
contrast to isotype-treated mice, no TRAP-positive oste-
oclasts were found in arthritis paw sections from day 11
after arthritis induction (Fig. 5d).
Preventive anti-RANKL treatment suppresses erosive joint
damage and development of subchondral granulation
tissue but has no effect on extraarticular new bone
formation
To determine the effect of anti-RANKL treatment on
joint destruction and new bone formation, we scored
arthritis paws from mice treated with anti-RANKL or
isotype control for inflammation, pannus formation,
granulation tissue development, cartilage damage,
bone resorption, and bone formation. The histological
scoring did not reveal any differences in inflammation
between anti-RANKL- and isotype-treated mice, nor
did it show differences in the extent of extraarticular
pannus tissue or cartilage damage (p > 0.05). However,
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Fig. 2 Inflammation in delayed-type hypersensitivity arthritis (DTHA) is accompanied by early cartilage damage and bone resorption that precedes
new bone formation. a Representative examples of Safranin O/Fast Green and collagen type X (COLX)- and osteocalcin (OC)-stained tissue sec-
tions of DTHA or control [phosphate-buffered saline (PBS)] paws at indicated time points. c cartilage, b bone, i inflammation, bm bone marrow, nc
new cartilage, nb new bone. Safranin O/Fast Green original magnification × 100, COLX and OC original magnification × 200. b Histological scores
of cartilage damage and bone resorption performed on Safranin O/Fast Green–stained tissue sections and of new bone formation performed on
COLX- and OC-stained sections (n = 10 per time point). c Assessment of endochondral or direct bone formation or both types in tissue sections
of methylated bovine serum albumin (mBSA)-challenged paws at indicated time points assessed on COLX- and OC-stained tissue sections.
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bone destruction was significantly reduced by anti-
RANKL treatment (p < 0.001) (Fig. 6a), and a marked
reduction was found in the magnitude of subchondral
granulation tissue in anti-RANKL-treated mice (Fig. 6a
and b). In contrast, new bone formation was com-
pletely unaffected by anti-RANKL treatment in the
DTHA model, indicating that new bone formation is
not linked to osteoclast activity in this model.
Discussion
In this study, we analyzed the spatiotemporal develop-
ment of joint destruction and bone formation in the
DTHA model. We show that cartilage damage and bone
destruction precede bone formation. Cartilage and bone
damage coincide with increased local cathepsin B pro-
teolytic activity, increased systemic MMP3 levels, and
development of invasive pannus tissue periarticularly
and at sites of the subchondral bone marrow. New bone
development was observed at apophyseal sites mediated
primarily by endochondral ossification and at diaphyseal
bone sites mediated by direct bone formation. This was
accompanied by upregulation of genes involved in endo-
chondral bone formation, such as MMP2, MMP9, and
MMP13 [18–20], and by induction of osteoblast-specific
genes, such as osteocalcin and ALP, in the paw tissue.
In accordance with findings in other arthritis models,
we found that osteoclasts are crucially involved in joint
destruction in DTHA. Osteoclast development from
osteoclast precursors, monocytes, and dendritic cells
(DCs) is induced by ligation of RANK by RANKL [22,
23]. RANKL was upregulated early after arthritis induc-
tion, and RANKL protein levels peaked on day 4 after
arthritis induction [15]. Activated osteoclasts were seen
on day 5 after arthritis induction and peaked on day 10.
They were located primarily at the apophyseal attach-
ment regions of the periarticular pannus tissue close to
vascular channels penetrating the bone [17] and at the
edges of the granulation tissue within the subchondral
bone marrow. Treatment with anti-RANKL abrogated
bone destruction in DTHA and prevented development
of the subchondral granulation tissue. This suggests that
osteoclast activity promotes generation of this subchon-
dral tissue, most likely by promoting invasion of peri-
articular pannus tissue or inflammatory mediators into
the bone marrow through the vascular channels. This
seems to be a critical step in joint destruction, as the
granulation tissue strongly contributes to the joint de-
struction process, which can be prevented by anti-
RANKL treatment. Similarly to our study, anti-RANKL
treatment resulted in reduced bone destruction in the
collagen antibody–induced arthritis model [23] and
RANKL−/− mice showed reduced bone erosion in the K/
BxN serum transfer arthritis model [24].
In contrast to anti-TNFα treatment, which abrogated
both cartilage and bone damage [15], anti-RANKL treat-
ment prevented only bone destruction and not cartilage
damage. This suggests that cartilage damage is mediated
independently of osteoclasts, most likely by proteolytic
enzymes such as metalloproteinases induced by proin-
flammatory cytokines. However, anti-RANKL treatment
also had a modest anti-inflammatory effect: It lowered
systemic levels of SAP and MMP3 after immunization
and mBSA challenge and resulted in slightly reduced
paw swelling at later points. Although RANK–RANKL
interaction may affect T effector cell generation by pro-
moting the survival and inflammatory cytokine produc-
tion of DCs [25], the fact that early paw swelling was
unaffected in anti-RANKL-treated mice suggests that
anti-RANKL treatment may constrain inflammation to
local tissue and prevent systemic spreading rather than
abrogating T-cell priming.
Inhibition of bone destruction by anti-RANKL treat-
ment had no preventive effect on new bone formation,
although bone erosion and bone formation occurred
sequentially in DTHA. Similarly, blocking RANKL
signaling in two different rat models of arthritis could
not prevent periarticular bone formation [26], and in
the DBA/1 SpA model inhibition of osteoclast activity
by zoledronate did not abrogate induction of anky-
losis either [14].
(See figure on previous page.)
Fig. 4 Delayed-type hypersensitivity arthritis (DTHA) is accompanied by enhanced proteolytic osteoclast activity and increased transcription of
genes associated with bone erosion and new bone formation. a Activity of the tissue-remodeling enzyme cathepsin B (CatB; mean and individual
measurements, n = 3–5) at indicated time points after arthritis induction in the methylated bovine serum albumin–challenged paw with subtracted
fluorophore intensity of the control paw as determined by in vivo fluorescence molecular tomographic imaging. b Serum levels (mean ± standard
error of the mean, n = 5–10) of matrix metalloproteinase 3 (MMP3) over the course of DTHA is shown. Dashed line represents the mean of naive mice
(n = 5). c Messenger RNA (mRNA) expression of genes associated with bone destruction (mean and individual measurements, n = 4) in paw tissue as
determined by mRNA deep sequencing. Significance of differences in levels in naive mice was determined using one-way analysis of variance (ANOVA)
with Dunnett’s posttest for multiple comparisons. *p < 0.05; **p < 0.01; ***p < 0.001. d mRNA expression of genes associated with bone formation and
tissue remodeling in paw tissue as determined by mRNA deep sequencing (mean and individual measurements, n = 4). Significance of differences in
levels in naive mice was determined using one-way ANOVA with Dunnett’s posttest for multiple comparisons. *p < 0.05; **p < 0.01; ***p < 0.001. BMP
bone morphogenetic protein; RANKL receptor activator of nuclear factor κB ligand, RPKM reads per kilobase per million reads, TRAP tartrate-resistant
acid phosphatase, CatK cathepsin K, DKK-1 dickkopf 1, TGF-β1 transforming growth factor β1
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BMP2, which is a growth factor that stimulates chon-
drocyte differentiation as well as osteoblast differenti-
ation, has been implicated in the process of bone
formation and ankylosis in the DBA/1 enthesitis model.
Thus, inhibition of BMP signaling by overexpression of
noggin, which is an endogenous BMP antagonist, inhib-
ited the onset and the progression of enthesitis [27]. In
our study, BMP2 and BMP7 were downregulated within
the arthritic paw, which is similar to findings in the
collagen-induced arthritis model [28]. While BMPs were
downregulated, we found upregulation of TGF-β1 after
acute inflammation in DTHA had subsided. TGF-β has
effects similar to those of BMPs on bone and chondro-
cyte precursors [29], suggesting that new bone formation
may be driven by TGF-β1 in DTHA. Moreover, expres-
sion of DKK-1, a Wnt pathway inhibitor that promotes
osteoblast differentiation, was not dysregulated during
early arthritis but was increased at day 8, when bone for-
mation had begun, which may indicate the presence of
feedback control of the aberrant bone formation.
Thus, extraarticular new bone formation in the DTHA
model is not dependent on the preceding osteoclastic
damage and seems differently regulated than in the
DBA/1 model of SpA. Elucidation of this mechanism is
desirable, as it may provide additional clues about the
development of enthesiophytes and the regulation of
inflammation-driven new bone formation. The shift
from inflammation to resolution of inflammation as well
as the presence of extensive extraarticular tissue damage
may promote new bone formation in the DTHA model.
Apart from that, we provide evidence for the impact of
the subchondral granulation tissue on bone destruction
and the crucial role of osteoclasts for development of
the subchondral bone marrow changes.
Fig. 5 Treatment with monoclonal antibody (mAb) against receptor
activator of nuclear factor κB ligand (anti-RANKL) leads to a small
reduction in local and systemic inflammation and a pronounced
reduction in osteoclastogenesis. Mice were treated with 500 μg of
anti-RANKL mAb or isotype control in 200 μl of phosphate-buffered
saline three times weekly from the time of immunization (day −7). a
Paw (top panel) and ankle (bottom panel) swelling in mice treated
with anti-RANKL or isotype control. The area under the curve (AUC)
was calculated for individual mice for days 0–11 after arthritis
induction, and data shown are mean ± standard error of the mean
(SEM) (n = 10). *p < 0.05; **p < 0.01 (Student’s t test). b Serum levels
(mean ± SEM, n = 10) of serum amyloid P component (SAP) and
matrix metalloproteinase 3 (MMP3) measured on days 0, 7, and 11
after arthritis induction by enzyme-linked immunosorbent assay.
*p < 0.05; **p < 0.01 (Student’s t test). Dashed line represents mean
value of n = 10 naive mice. c Serum levels of tartrate-resistant acid
phosphatase 5b (TRAP5b) and carboxy terminal telopeptide I
(CTX-I) in serum measured on day 11 after arthritis induction. d
Histochemical TRAP staining of paw sections from day 11 after
arthritis induction from isotype and anti-RANKL-treated mice
(two representative examples per treatment). Original magnification, ×
100. DTHA delayed-type hypersensitivity arthritis
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Conclusions
Bone destruction and bone formation occur sequentially
in the DTHA model. Blockade of RANKL prevents de-
velopment of subchondral granulation tissue and inhibits
bone destruction, but it has no effect on extraarticular
new bone formation.
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